Horizon Therapeutics plc: Data Support the Use of KRYSTEXXA

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment

Related Keywords

United States , Ireland , American , Brad Marder , Amanda Phraner , Clin Rheumatol , Tina Ventura , Abdul Abdellatif , Ray Gordon , Erin Linnihan , Instagram , Product Communications , Patients With Uncontrolled Gout Co , Linkedin , Twitter , Nasdaq , Exchange Commission , American Society Of Nephrology , Facebook , Baylor College Of Medicine Nephrology Division , Kidney Week , American Society , Baylor College , Medicine Nephrology Division , Kidney Hypertension Transplant Clinic , Increase Response Rates , Uncontrolled Gout Receiving , Uncontrolled Gout Patients Randomized , Receive Methotrexate , Heart Failure , Full Prescribing Information , Combination With Methotrexate , Patients With Uncontrolled Gout , Open Label Study , Pegloticase Response , Proof Of Concept Case , Randomized Placebo Controlled Study , Receiving Pegloticase , Primary Efficacy , Accepted Author , Vice President , Chief Investor Relations Officer , Investor Relations , Media Contact , Horizon , Herapeutics , Data , Support , Krystexxa , Egloticase , Injection , Ethotrexate , Treat , Uncontrolled , Out , People , Ith , Ild , Moderate , Hronic , Kidney , Disease ,